Max Meier

516 total citations
28 papers, 368 citations indexed

About

Max Meier is a scholar working on Molecular Biology, Biochemistry and Organic Chemistry. According to data from OpenAlex, Max Meier has authored 28 papers receiving a total of 368 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Molecular Biology, 5 papers in Biochemistry and 4 papers in Organic Chemistry. Recurrent topics in Max Meier's work include Eicosanoids and Hypertension Pharmacology (5 papers), Receptor Mechanisms and Signaling (4 papers) and Nitric Oxide and Endothelin Effects (3 papers). Max Meier is often cited by papers focused on Eicosanoids and Hypertension Pharmacology (5 papers), Receptor Mechanisms and Signaling (4 papers) and Nitric Oxide and Endothelin Effects (3 papers). Max Meier collaborates with scholars based in Switzerland, Germany and Italy. Max Meier's co-authors include H. Brünner, P. R. Hedwall, H. Rogg, Fred Basolo, Ralph G. Pearson, Fritz R. Bühler, Paul Erné, Ernst Bürgisser, A. Delini‐Stula and K. Krämer and has published in prestigious journals such as Circulation, Biochemical and Biophysical Research Communications and Journal of Medicinal Chemistry.

In The Last Decade

Max Meier

26 papers receiving 319 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Max Meier Switzerland 12 145 119 67 58 41 28 368
J. S. Stephenson United Kingdom 6 132 0.9× 140 1.2× 51 0.8× 57 1.0× 52 1.3× 8 463
K.W. Dungan United States 12 171 1.2× 138 1.2× 78 1.2× 76 1.3× 61 1.5× 23 505
Klaus Dietrich Bock Germany 10 93 0.6× 63 0.5× 93 1.4× 35 0.6× 42 1.0× 27 377
Takashi Kariya Japan 10 203 1.4× 133 1.1× 91 1.4× 20 0.3× 56 1.4× 18 449
L. H. Smith United States 10 213 1.5× 171 1.4× 88 1.3× 76 1.3× 64 1.6× 29 637
Allen W. Gomoll United States 12 165 1.1× 257 2.2× 50 0.7× 49 0.8× 45 1.1× 38 558
K. Stoepel Germany 12 194 1.3× 231 1.9× 67 1.0× 57 1.0× 91 2.2× 38 534
James L. Bergey United States 10 169 1.2× 190 1.6× 88 1.3× 58 1.0× 19 0.5× 11 360
Thomas L. Waldron United States 12 177 1.2× 190 1.6× 117 1.7× 46 0.8× 99 2.4× 25 473
C. M. Williams United States 13 146 1.0× 47 0.4× 42 0.6× 95 1.6× 52 1.3× 35 561

Countries citing papers authored by Max Meier

Since Specialization
Citations

This map shows the geographic impact of Max Meier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Max Meier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Max Meier more than expected).

Fields of papers citing papers by Max Meier

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Max Meier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Max Meier. The network helps show where Max Meier may publish in the future.

Co-authorship network of co-authors of Max Meier

This figure shows the co-authorship network connecting the top 25 collaborators of Max Meier. A scholar is included among the top collaborators of Max Meier based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Max Meier. Max Meier is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Meier, Max, Julie Callaert, Paolo Landoni, & Bart Van Looy. (2023). Co-patents in Europe: Methodological concerns, unfolding trends. Journal of Informetrics. 17(3). 101430–101430. 5 indexed citations
2.
Herold, Peter, J. W. Herzig, Walter Fuhrer, et al.. (1995). 5-Methyl-6-phenyl-1,3,5,6-tetrahydro-3,6-methano-1,5-benzodiazocine-2,4- dione (BA 41899): Representative of a Novel Class of Purely Calcium-Sensitizing Agents. Journal of Medicinal Chemistry. 38(15). 2946–2954. 36 indexed citations
3.
Erné, Paul, et al.. (1984). Enhancement of calcium influx in human platelets by CGP 28392, a novel dihydropyridine. Biochemical and Biophysical Research Communications. 118(3). 842–847. 53 indexed citations
4.
Bolli, Peter, Fritz R. Bühler, Ernst A. Raeder, et al.. (1981). Lack of beta-adrenoreceptor hypersensitivity after abrupt withdrawal of long-term therapy with oxprenolol.. Circulation. 64(6). 1130–1134. 16 indexed citations
5.
Hoffmann, Andreas & Max Meier. (1977). Comparison of the cardiovascular effects of phentolamine, sodium nitroprusside and nitroglycerin in anaesthetized cats (Comparison of vasodilators). Basic Research in Cardiology. 72(4). 411–420. 3 indexed citations
6.
Delini‐Stula, A. & Max Meier. (1976). Inhibitory effects of propranolol and oxprenolol on excitation induced by a MAO inhibitor and reserpine in the mouse. Neuropharmacology. 15(7). 383–388. 13 indexed citations
7.
Brünner, H., P. R. Hedwall, & Max Meier. (1971). General concepts in the use of?-blockers: The relative roles of specific and unspecific effects. Naunyn-Schmiedeberg s Archives of Pharmacology. 269(2-4). 219–231. 12 indexed citations
8.
Meier, Max. (1970). Effects of oxprenolol on cardiac contractile force, heart rate and coronary circulation.. PubMed. Suppl:15–21. 11 indexed citations
9.
Meier, Max, et al.. (1970). [Optical antipodes of adrenergic beta receptor blocking agent 1-(o-allyloxyphenoxy)-3-isopropylamino-2-propanol].. PubMed. 20(12). 1890–6. 2 indexed citations
10.
Brünner, H., et al.. (1968). [Pharmacological studies with 1-isopropylamino-3-(o-allyloxyphenoxy)-2-propanol-hydrochloride, an adrenergic beta-receptor blocking agent].. PubMed. 18(2). 164–70. 14 indexed citations
11.
Wilhelm, M., P. R. Hedwall, & Max Meier. (1967). o-Allyloxy-phenoxy-propanolamine, eine neue Gruppe adrenergischer β-Rezeptoren-Blocker. Cellular and Molecular Life Sciences. 23(8). 651–652. 2 indexed citations
12.
Brünner, H., P. R. Hedwall, L. Maître, & Max Meier. (1967). ANTIHYPERTENSIVE EFFECTS OF ALPHA‐METHYLATED CATECHOLAMINE ANALOGUES IN THE RAT*. British Journal of Pharmacology and Chemotherapy. 30(1). 108–122. 16 indexed citations
13.
Brünner, H., P. R. Hedwall, L. Maître, & Max Meier. (1966). [Modification of the eserine pressor effect by propranolol].. PubMed. 254(1). 45–55. 1 indexed citations
14.
Brünner, H., P. R. Hedwall, & Max Meier. (1965). Inhibition of acute effects of hydralazine by an adrenergicβ-receptor blocking agent. Cellular and Molecular Life Sciences. 21(3). 136–137. 5 indexed citations
15.
Meier, Max, et al.. (1965). Effects of Norepinephrine and Angiotensin II-amide on Coronary Flow and Myocardial Oxygen Consumption in the Cat. Cardiology. 47(3). 127–138. 4 indexed citations
16.
Brünner, H., P. R. Hedwall, & Max Meier. (1965). Influence of an adrenergicβ-receptor blocking agent on the effect of various hypotensive agents in the hypertensive rat. Cellular and Molecular Life Sciences. 21(4). 231–232. 15 indexed citations
17.
Bock, K. D., Max Meier, & F. Gross. (1964). Die Blutdruckwirkung gef��aktiver Substanzen bei Nebenniereninsuffizienz. Naunyn-Schmiedeberg s Archives of Pharmacology. 249(5). 455–63.
18.
Meier, Max, et al.. (1964). [HEMODYNAMICS OF THE RENAL MEDULLA. IV. DYE DILUTION CURVES IN DIFFERENT SEGMENTS OF THE RENAL MEDULLA].. PubMed. 279. 294–304. 7 indexed citations
19.
Meier, Max, H. Brechtelsbauer, & K. Krämer. (1964). H�modynamik des Nierenmarks. Pflügers Archiv - European Journal of Physiology. 279(4). 294–304. 10 indexed citations
20.
Bock, K. D., Robert M. Smith, & Max Meier. (1964). THE EFFECT OF ATROPINE ON CARDIOVASCULAR REACTIONS ELICITED BY CATECHOLAMINES, ANGIOTENSIN, HISTAMINE, SEROTONIN, AND ACETYLCHOLINE IN THE CONSCIOUS DOG. Survey of Anesthesiology. 8(4). 309???310–309???310. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by J. S. Stephenson Breakdown of academic impact, for papers by K.W. Dungan Breakdown of academic impact, for papers by Klaus Dietrich Bock Breakdown of academic impact, for papers by Takashi Kariya Breakdown of academic impact, for papers by L. H. Smith Breakdown of academic impact, for papers by Allen W. Gomoll Breakdown of academic impact, for papers by K. Stoepel Breakdown of academic impact, for papers by James L. Bergey Breakdown of academic impact, for papers by Thomas L. Waldron Breakdown of academic impact, for papers by C. M. Williams
Rankless by CCL
2026